US3887699A
(en)
|
1969-03-24 |
1975-06-03 |
Seymour Yolles |
Biodegradable polymeric article for dispensing drugs
|
US3854480A
(en)
|
1969-04-01 |
1974-12-17 |
Alza Corp |
Drug-delivery system
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
FR2413974A1
(fr)
|
1978-01-06 |
1979-08-03 |
David Bernard |
Sechoir pour feuilles imprimees par serigraphie
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
ATE12348T1
(de)
|
1980-11-10 |
1985-04-15 |
Gersonde Klaus Prof Dr |
Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
|
PH19942A
(en)
|
1980-11-18 |
1986-08-14 |
Sintex Inc |
Microencapsulation of water soluble polypeptides
|
US4675189A
(en)
|
1980-11-18 |
1987-06-23 |
Syntex (U.S.A.) Inc. |
Microencapsulation of water soluble active polypeptides
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
DE3218121A1
(de)
|
1982-05-14 |
1983-11-17 |
Leskovar, Peter, Dr.-Ing., 8000 München |
Arzneimittel zur tumorbehandlung
|
EP0102324A3
(de)
|
1982-07-29 |
1984-11-07 |
Ciba-Geigy Ag |
Lipide und Tenside in wässriger Phase
|
US4452775A
(en)
|
1982-12-03 |
1984-06-05 |
Syntex (U.S.A.) Inc. |
Cholesterol matrix delivery system for sustained release of macromolecules
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US4650764A
(en)
|
1983-04-12 |
1987-03-17 |
Wisconsin Alumni Research Foundation |
Helper cell
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
EP0350973B1
(de)
|
1983-09-26 |
1997-11-05 |
Udo Dr. Ehrenfeld |
Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
|
DE3474511D1
(en)
|
1983-11-01 |
1988-11-17 |
Terumo Corp |
Pharmaceutical composition containing urokinase
|
DE3413608A1
(de)
|
1984-04-11 |
1985-10-24 |
Hoechst Ag, 6230 Frankfurt |
Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
US5075109A
(en)
|
1986-10-24 |
1991-12-24 |
Southern Research Institute |
Method of potentiating an immune response
|
US5811128A
(en)
|
1986-10-24 |
1998-09-22 |
Southern Research Institute |
Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
|
US4897268A
(en)
|
1987-08-03 |
1990-01-30 |
Southern Research Institute |
Drug delivery system and method of making the same
|
ATE110108T1
(de)
|
1987-12-11 |
1994-09-15 |
Whitehead Biomedical Inst |
Genetische modifizierung von endothelialen zellen.
|
US5206152A
(en)
|
1988-04-08 |
1993-04-27 |
Arch Development Corporation |
Cloning and expression of early growth regulatory protein genes
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
JPH04507041A
(ja)
|
1988-12-13 |
1992-12-10 |
アメリカ合衆国 |
遺伝工学により修飾された内皮細胞およびその利用方法
|
AU5741590A
(en)
|
1989-05-04 |
1990-11-29 |
Southern Research Institute |
Improved encapsulation process and products therefrom
|
US5133974A
(en)
|
1989-05-05 |
1992-07-28 |
Kv Pharmaceutical Company |
Extended release pharmaceutical formulations
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
EP0479909B1
(en)
|
1989-06-29 |
1996-10-30 |
Medarex, Inc. |
Bispecific reagents for aids therapy
|
KR920007887B1
(ko)
|
1989-08-29 |
1992-09-18 |
스즈키 지도오샤 고오교오 가부시키가이샤 |
내연기관의 배기가스 정화장치
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5149655A
(en)
|
1990-06-21 |
1992-09-22 |
Agracetus, Inc. |
Apparatus for genetic transformation
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
KR100272077B1
(ko)
|
1990-08-29 |
2000-11-15 |
젠팜인터내셔날,인코포레이티드 |
이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
JPH06500923A
(ja)
|
1990-09-21 |
1994-01-27 |
カイロン コーポレイション |
パッケージング細胞
|
JP3249516B2
(ja)
|
1990-10-31 |
2002-01-21 |
ソマティクス セラピー コーポレイション |
遺伝子治療のためのレトロウイルスのベクター
|
ATE164395T1
(de)
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
CA2098849C
(en)
|
1990-12-20 |
2007-07-10 |
Ralph R. Weichselbaum |
Control of gene expression by ionizing radiation
|
CA2104396C
(en)
|
1991-02-19 |
2000-10-10 |
Jiing-Kuan Yee |
Viral particles having altered host range
|
US6565841B1
(en)
|
1991-03-15 |
2003-05-20 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
CA2102511A1
(en)
|
1991-05-14 |
1992-11-15 |
Paul J. Higgins |
Heteroconjugate antibodies for treatment of hiv infection
|
IT1247472B
(it)
|
1991-05-31 |
1994-12-17 |
Fidia Spa |
Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
US5407686A
(en)
|
1991-11-27 |
1995-04-18 |
Sidmak Laboratories, Inc. |
Sustained release composition for oral administration of active ingredient
|
US5470582A
(en)
|
1992-02-07 |
1995-11-28 |
Syntex (U.S.A.) Inc. |
Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
|
EP1013270A3
(en)
|
1992-12-02 |
2001-03-28 |
Alkermes Controlled Therapeutics, Inc. |
Controlled release growth hormone containing microspheres
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
ES2131676T3
(es)
|
1993-01-11 |
1999-08-01 |
Dana Farber Cancer Inst Inc |
Induccion de respuestas con linfocitos t citotoxicos.
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
FR2702160B1
(fr)
|
1993-03-02 |
1995-06-02 |
Biovecteurs As |
Vecteurs particulaires synthétiques et procédé de préparation.
|
FR2704145B1
(fr)
|
1993-04-21 |
1995-07-21 |
Pasteur Institut |
Vecteur particulaire et composition pharmaceutique le contenant.
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US6372716B1
(en)
|
1994-04-26 |
2002-04-16 |
Genetics Institute, Inc. |
Formulations for factor IX
|
FR2723849B1
(fr)
|
1994-08-31 |
1997-04-11 |
Biovector Therapeutics Sa |
Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
|
ATE197398T1
(de)
|
1994-09-09 |
2000-11-11 |
Takeda Chemical Industries Ltd |
Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
DE69618938T2
(de)
|
1995-03-28 |
2002-10-31 |
Fidia Advanced Biopolymers Srl |
Nanosphären mit einem biokompatiblen polysaccharid
|
SK281571B6
(sk)
|
1995-06-07 |
2001-05-10 |
Alkermes Controlled Therapeutics, Inc. |
Prostriedok na trvalé uvoľňovanie ľudského rastového hormónu
|
ZA965368B
(en)
|
1995-07-14 |
1997-01-14 |
Novo Nordisk As |
A pharmaceutical formulation
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
US5736152A
(en)
|
1995-10-27 |
1998-04-07 |
Atrix Laboratories, Inc. |
Non-polymeric sustained release delivery system
|
US6080728A
(en)
|
1996-07-16 |
2000-06-27 |
Mixson; A. James |
Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
|
CA2263705C
(en)
|
1996-08-19 |
2007-12-04 |
Nancy Smyth-Templeton |
Novel sandwich liposome complexes comprising a biologically active agent
|
US6610833B1
(en)
|
1997-11-24 |
2003-08-26 |
The Institute For Human Genetics And Biochemistry |
Monoclonal human natural antibodies
|
BR9813365A
(pt)
|
1997-12-05 |
2004-06-15 |
Scripps Research Inst |
Método para produção e humanização de um anticorpo monoclonal de rato
|
DE69911175T2
(de)
|
1998-02-12 |
2004-07-29 |
Apovia, Inc., San Diego |
Strategisch modifizierte hepatitis b kernproteine und ihre derivate
|
US6682736B1
(en)
|
1998-12-23 |
2004-01-27 |
Abgenix, Inc. |
Human monoclonal antibodies to CTLA-4
|
US6566329B1
(en)
|
1999-06-28 |
2003-05-20 |
Novo Nordisk A/S |
Freeze-dried preparation of human growth hormone
|
CA2393869A1
(en)
|
1999-12-15 |
2001-06-21 |
Genetech,Inc. |
Shotgun scanning, a combinatorial method for mapping functional protein epitopes
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
KR100857943B1
(ko)
|
2000-11-30 |
2008-09-09 |
메다렉스, 인코포레이티드 |
인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
WO2003026577A2
(en)
|
2001-09-24 |
2003-04-03 |
Seattle Genetics, Inc. |
P-amidobenzylethers in drug delivery agents
|
US8209006B2
(en)
|
2002-03-07 |
2012-06-26 |
Vgx Pharmaceuticals, Inc. |
Constant current electroporation device and methods of use
|
US7245963B2
(en)
|
2002-03-07 |
2007-07-17 |
Advisys, Inc. |
Electrode assembly for constant-current electroporation and use
|
JP4753578B2
(ja)
|
2002-06-03 |
2011-08-24 |
ジェネンテック, インコーポレイテッド |
合成抗体ファージライブラリー
|
EP1531757B1
(en)
|
2002-07-19 |
2016-09-07 |
Omeros Corporation |
Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
|
ES2556641T3
(es)
|
2002-07-31 |
2016-01-19 |
Seattle Genetics, Inc. |
Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
AU2004205631A1
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
AU2004247071B2
(en)
|
2003-05-30 |
2010-03-11 |
University Of South Florida |
Method for the treatment of malignancies
|
KR101438983B1
(ko)
|
2003-11-06 |
2014-09-05 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
US7375078B2
(en)
|
2004-02-23 |
2008-05-20 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
US7837980B2
(en)
|
2004-03-02 |
2010-11-23 |
Seattle Genetics, Inc. |
Partially loaded antibodies and methods of their conjugation
|
US7592326B2
(en)
|
2004-03-15 |
2009-09-22 |
Karaolis David K R |
Method for stimulating the immune, inflammatory or neuroprotective response
|
US7569555B2
(en)
|
2004-03-15 |
2009-08-04 |
Karaolis David K R |
Method for stimulating the immune, inflammatory or neuroprotective response
|
EP1576952A1
(en)
|
2004-03-18 |
2005-09-21 |
OctoPlus Technologies B.V. |
Hydrogel microspheres with improved release profile
|
CN1961003B
(zh)
|
2004-03-31 |
2013-03-27 |
健泰科生物技术公司 |
人源化抗TGF-β抗体
|
US7785903B2
(en)
|
2004-04-09 |
2010-08-31 |
Genentech, Inc. |
Variable domain library and uses
|
WO2006132670A2
(en)
|
2004-11-12 |
2006-12-14 |
Seattle Genetics, Inc. |
Auristatins having an aminobenzoic acid unit at the n terminus
|
US7923251B2
(en)
|
2005-02-23 |
2011-04-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method and apparatus for avalanche-mediated transfer of agents into cells
|
US8101169B2
(en)
|
2005-02-23 |
2012-01-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Ocular gene therapy using avalanche-mediated transfection
|
ES2427646T5
(es)
|
2005-05-09 |
2017-08-22 |
Ono Pharmaceutical Co., Ltd. |
Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
|
JP4658125B2
(ja)
|
2005-06-28 |
2011-03-23 |
パイオニア株式会社 |
放送受信装置、妨害検出装置および妨害検出方法
|
MX2007015942A
(es)
|
2005-07-01 |
2008-03-07 |
Medarex Inc |
Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
|
ES2908458T3
(es)
|
2005-07-18 |
2022-04-29 |
Seagen Inc |
Conjugados de fármaco-enlazador de beta-glucurónido
|
EP1957531B1
(en)
|
2005-11-07 |
2016-04-13 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
EP1782826A1
(en)
|
2005-11-08 |
2007-05-09 |
GBF Gesellschaft für Biotechnologische Forschung mbH |
PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
|
EP1973951A2
(en)
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
JP2009536527A
(ja)
|
2006-05-09 |
2009-10-15 |
ジェネンテック・インコーポレーテッド |
最適化されたスキャフォールドを備えた結合ポリペプチド
|
JP4616237B2
(ja)
|
2006-11-07 |
2011-01-19 |
日本電信電話株式会社 |
シリコン化合物薄膜の形成方法
|
CN100592373C
(zh)
|
2007-05-25 |
2010-02-24 |
群康科技(深圳)有限公司 |
液晶显示面板驱动装置及其驱动方法
|
RS53072B
(en)
|
2007-06-18 |
2014-04-30 |
Merck Sharp & Dohme B.V. |
HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1
|
KR20100097737A
(ko)
|
2008-01-15 |
2010-09-03 |
에프. 호프만-라 로슈 아게 |
Ccr5에 대한 어푸코실화된 항체 및 이의 용도
|
PT2242773T
(pt)
|
2008-02-11 |
2017-09-15 |
Cure Tech Ltd |
Anticorpos monoclonais para o tratamento de tumores
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
EP2328919A2
(en)
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
WO2010027423A2
(en)
|
2008-08-25 |
2010-03-11 |
Amplimmune, Inc. |
Compositions of pd-1 antagonists and methods of use
|
CN105274125A
(zh)
|
2008-09-26 |
2016-01-27 |
托卡根公司 |
基因治疗载体和胞嘧啶脱氨酶
|
US8829173B2
(en)
|
2008-09-26 |
2014-09-09 |
Tocagen Inc. |
Recombinant vectors
|
HUE034832T2
(hu)
|
2008-12-09 |
2021-12-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
|
US8741295B2
(en)
|
2009-02-09 |
2014-06-03 |
Universite De La Mediterranee |
PD-1 antibodies and PD-L1 antibodies and uses thereof
|
EP3546583A1
(en)
|
2009-06-17 |
2019-10-02 |
Tocagen Inc. |
Producer cells for replication competent retroviral vectors
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
WO2012012736A2
(en)
|
2010-07-23 |
2012-01-26 |
The Ohio State University |
Method of treating a viral infection dysfunction by disrupting an adenosine receptor pathway
|
US9669049B2
(en)
|
2010-10-31 |
2017-06-06 |
Tocagen Inc. |
Compositions comprising gamma retrovirus vectors and methods of treating proliferative disorders
|
US9405700B2
(en)
|
2010-11-04 |
2016-08-02 |
Sonics, Inc. |
Methods and apparatus for virtualization in an integrated circuit
|
CN103732238A
(zh)
|
2011-06-08 |
2014-04-16 |
奥瑞基尼探索技术有限公司 |
用于免疫调节的治疗性化合物
|
CN104159911A
(zh)
|
2012-03-07 |
2014-11-19 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的模拟肽化合物
|
US11065311B2
(en)
|
2012-10-25 |
2021-07-20 |
Denovo Biopharma Llc |
Retroviral vector with mini-promoter cassette
|
EP2911736A4
(en)
|
2012-10-25 |
2016-06-15 |
Oncosec Medical Inc |
electroporation
|
EA201590396A1
(ru)
|
2012-12-13 |
2015-12-30 |
Адуро Биотек, Инк. |
Композиция, содержащая циклические пуриновые динуклеотиды с определенной стереохимией, и способ ее получения и применения
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
JP2016524593A
(ja)
|
2013-04-29 |
2016-08-18 |
メモリアル スローン−ケタリング キャンサー センター |
セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
|
MY175308A
(en)
|
2013-05-18 |
2020-06-18 |
Aduro Biotech Inc |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
JP2016526920A
(ja)
|
2013-08-05 |
2016-09-08 |
トカジェン インコーポレーテッド |
最適化a−バルジを有する組換えベクター
|
KR101540319B1
(ko)
|
2013-10-01 |
2015-07-30 |
한국생명공학연구원 |
cyb5R3 유전자 또는 단백질을 유효성분으로 포함하는 암 예방 및 치료용 약학적 조성물
|
US11230719B2
(en)
|
2014-03-26 |
2022-01-25 |
Denovo Biopharma Llc |
Retroviral vector having immune-stimulating activity
|
ES2692226T3
(es)
|
2014-06-04 |
2018-11-30 |
Glaxosmithkline Intellectual Property Development Limited |
Dinucleótidos cíclicos como moduladores de STING
|
US20170209574A1
(en)
|
2014-10-03 |
2017-07-27 |
Novartis Ag |
Combination therapies
|
EP3546473A1
(en)
|
2014-12-16 |
2019-10-02 |
Kayla Therapeutics |
Cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
|
WO2016112359A1
(en)
|
2015-01-09 |
2016-07-14 |
Oncosec Medical Incorporated |
Method for the treatment of malignancies
|
PE20171448A1
(es)
|
2015-03-10 |
2017-10-02 |
Aduro Biotech Inc |
Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
|
CA2981049A1
(en)
|
2015-03-26 |
2016-09-29 |
Oncosec Medical Incorporated |
Combination of an immunostimulatory cytokine and a checkpoint inhibitor for the treatment of malignancies
|
CA2981474A1
(en)
|
2015-03-31 |
2016-10-06 |
Oncosec Medical Incorporated |
Systems and methods for improved tissue-sensing based electroporation
|
MA42608A
(fr)
|
2015-08-13 |
2018-06-20 |
Merck Sharp & Dohme |
Composés de di-nucléotide cyclique en tant qu'agonistes sting (stimulateur de gène interféron)
|
CA2996797A1
(en)
|
2015-09-04 |
2017-03-09 |
Tocagen Inc. |
Recombinant vectors comprising 2a peptide
|
AU2016343993A1
(en)
|
2015-10-28 |
2018-05-10 |
Aduro Biotech, Inc. |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
JP2019509014A
(ja)
|
2015-11-23 |
2019-04-04 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
Cd39血管アイソフォームターゲティング剤
|
US11713467B2
(en)
|
2015-12-18 |
2023-08-01 |
Oncosec Medical Incorporated |
Plasmid constructs for heterologous protein expression and methods of use
|
CA3051640A1
(en)
*
|
2017-03-16 |
2018-09-20 |
Innate Pharma |
Compositions and methods for treating cancer
|
CN111448211B
(zh)
*
|
2017-07-31 |
2024-06-07 |
翠舒拉治疗股份有限公司 |
抗cd39抗体、包含抗cd39抗体的组合物和使用抗cd39抗体的方法
|